Objective:

The article examines the objective, findings, and clinical context described in Looking Beyond Symptoms in Psychiatric Drug Development.

Approach:

• Interview perspective: Tanya Wallace, PhD, AbbVie’s VP and Global Head of Neuroscience Discovery Research, discusses changes in psychiatric R&D.
• Translational tools: The interview describes EEG, receptor-occupancy imaging, resting-state and task-based fMRI, fluid biomarkers, and computational methods used or explored to connect preclinical findings with human studies.
• Biomarker validation: Preclinical comparisons of brain tissue, CSF, and plasma biomarkers, followed by complementary clinical measures such as receptor-occupancy studies, are described as ways to assess whether peripheral changes reflect central effects.

Key Findings:

• Wallace says psychiatric R&D has shifted from reliance mainly on symptom clusters and clinical observations toward greater use of human genetics, circuit biology, and translational biomarkers.
• EEG and imaging approaches are used or investigated to assess target engagement, support dose selection, and examine drug effects on brain activity and networks.
• Computational and multimodal methods may help analyze clinical, imaging, EEG, and fluid-biomarker data and identify disease subgroups.
• Wallace gives an immunometabolic profile in some people with depression, including elevated inflammatory cytokines and other inflammatory biomarkers, as an example of a potential subpopulation signal.
• The interview notes that the relationship between peripheral biomarkers and brain disease requires validation.

Interpretation:

Wallace characterizes the field as having improved tools for studying psychiatric biology and patient heterogeneity, while emphasizing that substantial work remains.

Limitations:

• This is an interview and does not report a clinical trial or systematic review.
• The context provides no quantitative results or independent evaluation of the approaches discussed.
• The relationship between blood-based biomarkers and processes in the brain remains an open question in the interview.

Sources:

• Article context provided by the user